Action PMGMU PRIVETERRA ACQUISITION CORP. II
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues Priveterra Acquisition Corp. II Nasdaq

Actions

PMGMU

US8765452037

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
AEON Biopharma Reports First Quarter 2024 Financial Results
AEON Biopharma Provides Update on Development Pipeline
Priveterra Acquisition Corp. II(NasdaqCM:PMGM) dropped from NASDAQ Composite Index
Priveterra Acquisition Corp. II Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
AEON Biopharma Announces Redemption of Public Warrants - March 29, 2024
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants
AEON Biopharma Announces Redemption of Public Warrants
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine
Priveterra Acquisition Corp. II Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
AEON Biopharma Reports Third Quarter 2023 Financial Results
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache
Priveterra Acquisition Corp. II Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Tastemaker Acquisition Corp. has Changed its Name to Priveterra Acquisition Corp. II
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action PMGM
  4. Action PMGMU
  5. Actualités Priveterra Acquisition Corp. II
  6. Autres langues